Hydroxyurea, the first approved drug for sickle cell disease, decreases sickle hemoglobin
polymerization by inducing fetal hemoglobin. Its effects in young children are excellent; …

Sickle cell disease (SCD) is a common genetic blood disorder associated with acute and
chronic pain, progressive multiorgan damage, and early mortality. Recent advances in …

Introduction Sickle cell disease (SCD) describes a group of heritable blood disorders
caused by the polymerization of sickle hemoglobin (HbS). HbS polymerization leads to …

Targeting the primary pathogenic event of sickle cell disease (SCD), the polymerization of
sickle hemoglobin (HbS), may prevent downstream clinical events. Mitapivat, an oral …

Introduction The substitution of glutamic acid by valine on the ß-globin chain produces the
hemoglobin S variant responsible for sickle cell disease (SCD), a disorder that affects …

Introduction Until recently, the treatment of sickle cell disease (SCD) for a long time has
been limited to hydroxycarbamide alone. SCD is characterized by hemoglobin (Hb) …

Voxelotor is designed to impeded the polymerization of sickle haemoglobin. Although FDA-
approved, its place in the treatment of sickle cell anaemia remains controversial. A report in …

Background Sickle cell disease is an inherited disorder characterized by the presence of
sickle hemoglobin (HbS). The process of Hb molecule polymerization is a pivotal step in the …

Background Sickle cell disease is a fatal systemic condition characterized by acute painful
episodes, persistent anemia, ongoing organ damage, organ infarction, and a markedly …

In particular, diarrhoea occurred in 23% of patients receiving voxelotor 1500 mg in the
HOPE trial, more than double the frequency observed with placebo (11%). 19 Pro-active …